November 12, 2014 by Brad Perriello
Merger & acquisition activity in the medtech sector stayed strong during the 3rd quarter, according to PricewaterhouseCoopers.
The merger & acquisition frenzy that consumed the medical device industry during the 2nd quarter stayed strong during the ensuing period, although the value of the Q3 deals slipped a bit, according to PricewaterhouseCoopers.
Medtech posted more deals during Q3, going from 11 to 13 deals on a sequential-quarter basis, according to PwC’s Pharmaceutical & Life Sciences Deals Insights Quarterly.
But the value of the deals declined from $5.6 billion to $3.6 billion during the 3rd quarter, compared with Q2, and slid 38.1% from Q3 2013, according to the report.